Venlafaxine CF 225 mg, harde capsules met verlengde afgifte

Country: Holland

Tungumál: hollenska

Heimild: CBG-MEB (College ter Beoordeling van Geneesmiddelen)

Virkt innihaldsefni:

VENLAFAXINEHYDROCHLORIDE SAMENSTELLING overeenkomend met ; VENLAFAXINE

Fáanlegur frá:

Centrafarm B.V. Nieuwe Donk 3 4879 AC ETTEN LEUR

ATC númer:

N06AX16

INN (Alþjóðlegt nafn):

VENLAFAXINEHYDROCHLORIDE COMPOSITION corresponding to ; VENLAFAXINE

Lyfjaform:

Capsule met verlengde afgifte, hard

Samsetning:

AMMONIA (E 527) ; AZORUBINE (E 122) ; BLAUWE INKT ; CELLULOSE, MICROKRISTALLIJN (E 460) ; COPOVIDON ; ETHYLCELLULOSE (E 462) ; GELATINE (E 441) ; INDIGOKARMIJN ALUMINIUMLAK (E 132) ; MAGNESIUMSTEARAAT (E 470b) ; POVIDON K 90 (E 1201) ; PROPYLEENGLYCOL (E 1520) ; SCHELLAK (E 904) ; SILICIUMDIOXIDE (E 551) ; TALK (E 553 B) ; TITAANDIOXIDE (E 171), AMMONIA (E 527) ; AZORUBINE (E 122) ; BLAUWE INKT ; CELLULOSE, MICROKRISTALLIJN (E 460) ; COPOVIDON ; ETHYLCELLULOSE (E 462) ; GELATINE (E 441) ; INDIGOKARMIJN ALUMINIUMLAK (E 132) ; MAGNESIUMSTEARAAT (E 470b) ; POVIDON K 90 (E 1201) ; PROPYLEENGLYCOL (E 1520) ; SCHELLAK (E 904) ; SILICIUMDIOXIDE (E 551) ; TALK (E 553 B) ; TITAANDIOXIDE (E 171),

Stjórnsýsluleið:

Oraal gebruik

Lækningarsvæði:

Venlafaxine

Vörulýsing:

Hulpstoffen: AMMONIA (E 527); AZORUBINE (E 122); BLAUWE INKT; CELLULOSE, MICROKRISTALLIJN (E 460); COPOVIDON; ETHYLCELLULOSE (E 462); GELATINE (E 441); INDIGOKARMIJN ALUMINIUMLAK (E 132); MAGNESIUMSTEARAAT (E 470b); POVIDON K 90 (E 1201); PROPYLEENGLYCOL (E 1520); SCHELLAK (E 904); SILICIUMDIOXIDE (E 551); TALK (E 553 B); TITAANDIOXIDE (E 171);

Leyfisdagur:

2017-10-18

Upplýsingar fylgiseðill

PACKAGE LEAFLET: INFORMATION FOR THE USER
VENLAFAXINE CF 37,5 MG, HARDE CAPSULES MET VERLENGDE AFGIFTE
VENLAFAXINE CF 75 MG, HARDE CAPSULES MET VERLENGDE AFGIFTE
VENLAFAXINE CF 150 MG, HARDE CAPSULES MET VERLENGDE AFGIFTE
VENLAFAXINE CF 225 MG, HARDE CAPSULES MET VERLENGDE AFGIFTE
Venlafaxine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT
CONTAINS IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1. What [product name] is and what is used for
2. What you need to know before you take [product name]
3. How to take [product name]
4. Possible side effects
5. How to store [product name]
6. Contents of the pack and other information
1. WHAT [PRODUCT NAME] IS AND WHAT IT IS USED FOR
[product name] contains the active substance venlafaxine.
[product name] is an antidepressant that belongs to a group of
medicines called serotonin
and norepinephrine reuptake inhibitors (SNRIs). This group of
medicines is used to treat
depression and other conditions such as anxiety disorders. It is
thought that people who are
depressed and/or anxious have lower levels of serotonin and
noradrenaline in the brain. It is
not fully understood how antidepressants work, but they may help by
increasing the levels of
serotonin and noradrenaline in the brain.
[product name] is a treatment for adults with depression. It is also a
treatment for adults with
the following anxiety disorders: generalised anxiety disorder, social
anxiety disorder (fear or
avoidance of social situations) and panic disorder (panic attacks).
Treating depression or
anxiety disorders properly is important to help yo

Vara einkenni

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT
Venlafaxine CF 37,5 mg, harde capsules met verlengde afgifte
Venlafaxine CF 75 mg, harde capsules met verlengde afgifte
Venlafaxine CF 150 mg, harde capsules met verlengde afgifte
Venlafaxine CF 225 mg, harde capsules met verlengde afgifte
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
[Product name] 37.5 mg prolonged-release capsules, hard:
Each
capsule
contains
42.45 mg
venlafaxine
hydrochloride
equivalent
to
37.5 mg
venlafaxine.
[Product name] 75 mg prolonged-release capsules, hard:
Each capsule contains 84.9 mg venlafaxine hydrochloride equivalent to
75 mg venlafaxine.
[Product name] 150 mg prolonged-release capsules, hard:
Each
capsule
contains
169.8 mg
venlafaxine
hydrochloride
equivalent
to
150 mg
venlafaxine.
Excipients with known effect
Contains 0.2 mg allura red AC (E129) and 0.4 mg sunset yellow FCF
(E110).
[Product name] 225 mg prolonged-release capsules, hard:
Each
capsule
contains
254.7 mg
venlafaxine
hydrochloride
equivalent
to
225 mg
venlafaxine.
Excipients with known effect
Contains 0.02 mg carmoisine.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Prolonged-release capsule, hard
[Product name] 37.5 mg prolonged-release capsules, hard:
Light grey opaque / peach opaque, size ‘3’ hard gelatin capsules
of approximately 15.40 mm
to 16.20 mm having thick and thin radial circular band on the body in
red ink and thick and
thin radial circular band on the cap in red ink. The capsule is filled
with 3 white to off-white,
round, biconvex, film coated mini tablets of 12.5 mg each.
[Product name] 75 mg prolonged-release capsules, hard:
Peach opaque / peach opaque, size ‘1’ hard gelatin capsules of
approximately 18.90 mm to
19.70 mm having thick and thin radial circular band on the body in red
ink and thick and thin
radial circular band on the cap in red ink. The capsule is filled with
6 white to off-white, round,
biconvex, film coated mini tablets of 12.5 mg each.
[Product name] 150 mg prolonged-release capsules